Page last updated: 2024-11-05

phenyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenyl ether, also known as diphenyl ether, is an organic compound with the formula (C6H5)2O. It is a colorless liquid with a sweet, aromatic odor. Phenyl ether is used as a solvent, a heat transfer fluid, and a component of hydraulic fluids. It is also used in the synthesis of other organic compounds. Phenyl ether is produced by the reaction of phenol with benzene in the presence of a catalyst. The compound is non-polar, and its dipole moment is close to zero. It is also relatively unreactive, and its chemical stability makes it suitable for use in a variety of applications.'

diphenyl ether : An aromatic ether in which the oxygen is attached to two phenyl substituents. It has been found in muscat grapes and vanilla. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7583
CHEMBL ID38934
CHEBI ID39258
SCHEMBL ID12286
MeSH IDM0099009

Synonyms (105)

Synonym
benzene,1'-oxybis-
nsc-19311
ether, diphenyl-
diphenyl ether
phenoxybenzene
phenyl ether
101-84-8
nsc19311
wln: ror
biphenyl oxide
diphenyl oxide
phenyl oxide
benzene, phenoxy-
benzene, 1,1'-oxybis-
inchi=1/c12h10o/c1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h1-10
NCGC00091303-01
geranium crystals
ai3-00749
fema no. 3667
ccris 5912
einecs 202-981-2
brn 1364620
ether, diphenyl
oxydiphenyl
phenyl ether, vapor
hsdb 934
nsc 19311
chemcryl jk-eb
diphenyl ether, >=99%, fg
nsc174083
nsc-174083
32576-61-7
diphenyl ether, reagentplus(r), >=99%
1,1'-oxydibenzene
oxybisbenzene
CHEBI:39258 ,
diphenylaether
diphenylether
1,1'-oxybis(benzene)
diphenyloxid
1,1'-oxybisbenzene
NCGC00091303-02
diphenyl ether, reagentplus(r), 99%
1-phenoxybenzene
CHEMBL38934
P0177
AKOS000120215
A800474
NCGC00091303-03
phenoxy-benzene
NCGC00256450-01
tox21_302777
cas-101-84-8
dtxcid701847
dtxsid9021847 ,
NCGC00259826-01
tox21_202277
unii-3o695r5m1u
4-06-00-00568 (beilstein handbook reference)
3o695r5m1u ,
ec 202-981-2
FT-0617056
FT-0625233
diphenyl-ether
oxydibenzene
propofol impurity i [ep impurity]
diphenyl ether [inci]
diphenyl ether [hsdb]
diphenyl ether [fhfi]
diphenyl ether [fcc]
diphenyl ether [mi]
SCHEMBL12286
4-phenoxybenzene
diphenyether
phoph
1,1'-oxybis-benzene
1-phenoxy benzene
ph2o
(4-phenoxy)benzene
STR00684
mfcd00003034
J-000505
J-520381
F1908-0183
diphenyl ether, selectophore(tm), >=99.9%
diphenyl ether, saj first grade, >=98.0%
diphenyl ether, vetec(tm) reagent grade, 98%
1,1'-oxybisbenzene, 9ci
1,1-oxybisbenzene
phenyl ether (8ci)
fema 3667
phenyl ether, 8ci
diphenyloxide
CS-0015060
Q419453
diphenyl-d10 ether
cis-12-octadecenoicacidmethylester
AMY10830
STL199168
D78034
di-phenyl ether
EN300-18028
HY-Y0339
propofol impurity i (ep impurity)
phenyl ether, fume

Research Excerpts

Actions

ExcerptReferenceRelevance
"Diphenyl ether derivatives inhibit mycobacterial cell wall synthesis by inhibiting an enzyme, enoyl-acyl carrier protein reductase (InhA), which catalyses the last step in the fatty acid synthesis cycle of genus Mycobacterium. "( Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents.
Arora, K; Boshoff, HI; Gautham Shenoy, G; Sridhar, B; Tiwari, AP; Vandana, KE; Varadaraj Bhat, G, 2020
)
1.52

Toxicity

ExcerptReferenceRelevance
" DP caused genetic effects in yeast with and without activating system, while the two chemicals appeared to be ineffective in Salmonella up to toxic levels."( Genotoxicity and teratogenicity of diphenyl and diphenyl ether: a study of sea urchins, yeast, and Salmonella typhimurium.
Bauer, C; Bronzetti, G; Ciajolo, A; Corsi, C; Esposito, A; Giordano, GG; Nieri, R; Pagano, G; Quinto, I; Vamvakinos, E, 1983
)
0.52
" Generally, the PentaBDEs seem to cause adverse effects at the comparably lowest dose, whereas much higher doses were needed for effects of the DecaBDEs."( Toxic effects of brominated flame retardants in man and in wildlife.
Darnerud, PO, 2003
)
0.32
" General behavior adverse effects were observed, and poisoned mouse were dissected to observe visceral lesions."( Acute oral toxicity and liver oxidant/antioxidant stress of halogenated benzene, phenol, and diphenyl ether in mice: a comparative and mechanism exploration.
Feng, M; Shi, J; Wang, Z; Wei, Z; Zhang, X, 2013
)
0.61
" These findings highlight the importance of examining co-exposures to fully understand the potential toxic effects."( In vitro cytotoxicity assessment of a West Virginia chemical spill mixture involving 4-methylcyclohexanemethanol and propylene glycol phenyl ether.
Boyd, J; Fabyanic, EB; Han, AA; Miller, JV; Mouch, JA; Prediger, MS; Prince, N, 2017
)
0.66

Bioavailability

ExcerptReferenceRelevance
" Decabromodiphenyl ether (BDE-209) is reported both in the general population and in occupationally exposed persons showing the bioavailability of this high molecular weight compound."( A review on human exposure to brominated flame retardants--particularly polybrominated diphenyl ethers.
Bergman, A; Patterson, DG; Sjödin, A, 2003
)
0.92
" The next step in optimization of the pharmacophore for preclinical evaluation is modification of the B ring to increase the bioavailability to that required for oral delivery."( Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.
amEnde, CW; Amin, AG; Boyne, ME; Chatterjee, D; Gruppo, V; Heaslip, D; Lenaerts, A; Lu, H; Slayden, RA; Sullivan, TJ; Tonge, PJ, 2007
)
0.54
" The toxicity and bioavailability of PBDEs are variable for different congeners, with some congeners showing dioxin-like activities and estrogenicity."( Biodegradation of diphenyl ether and transformation of selected brominated congeners by Sphingomonas sp. PH-07.
Chang, YS; Crowley, DE; Kim, YM; Murugesan, K; Nam, IH; Schmidt, S, 2007
)
0.66
" Promising members of our previously reported 2-aminoquinoline class of nNOS inhibitors, although orally bioavailable and brain-penetrant, suffer from unfavorable off-target binding to other CNS receptors, and they resemble known promiscuous binders."( Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
Cinelli, MA; Kang, S; Li, H; Martásek, P; Pensa, AV; Poulos, TL; Roman, LJ; Silverman, RB, 2015
)
1.86

Dosage Studied

ExcerptRelevanceReference
" All groups were dosed at a constant 2 ml/kg body weight volume of DPE in the DEP vehicle at concentrations to administer 0, 100, 300 or 1000 mg DPE/kg body weight/day."( Evaluation of the dermal subchronic toxicity of diphenyl ether in the rat.
Api, AM; Ford, RA, 2003
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
diphenyl ethers degradation612

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.23870.003245.467312,589.2998AID2517
GLI family zinc finger 3Homo sapiens (human)Potency49.99330.000714.592883.7951AID1259369
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency56.09340.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.54420.000817.505159.3239AID1159527
farnesoid X nuclear receptorHomo sapiens (human)Potency0.00400.375827.485161.6524AID588527
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.36470.000229.305416,493.5996AID743069; AID743075
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.58960.001723.839378.1014AID743083
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.05430.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene A-4 hydrolaseHomo sapiens (human)AC506.01006.01006.01006.0100AID410363
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID385221Lipophilicity, log P of the compound2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and screening of mono- and di-aryl technetium and rhenium metallocarboranes. A new class of probes for the estrogen receptor.
AID410366Activation of aminopeptidase activity of human recombinant leukotriene A4 hydrolase expressed in Escherichia coli assessed as p-nitroanilide release at 100 uM by spectrophotometry2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives.
AID21661Calculated partition coefficient (clogP) (PALLAS)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class.
AID410363Activation of aminopeptidase activity of human recombinant leukotriene A4 hydrolase expressed in Escherichia coli assessed as p-nitroanilide release by spectrophotometry2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives.
AID86389Inhibitory effect on L-triiodothyronine (L-T3) uptake by human HepG2 hepatoma cells at an application dose 10E-5 M1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class.
AID19429Partition coefficient (logP)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class.
AID410362Inhibition of epoxide hydrolase activity of human recombinant leukotriene A4 hydrolase expressed in Escherichia coli assessed as LTB4 production at 100 uM by RP-HPLC2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives.
AID1331301n-Octanol/water partition coefficient, log P of the compound by HPLC method
AID19211Calculated partition coefficient (clogP)2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Utility of boron clusters for drug design. Hansch-fujita hydrophobic parameters pi of dicarba-closo-dodecaboranyl groups.
AID13312991-octanol/D2O distribution coefficient, log D of the compound at pH 7.4 by 1H NMR spectroscopic analysis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (184)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (15.22)18.7374
1990's9 (4.89)18.2507
2000's70 (38.04)29.6817
2010's59 (32.07)24.3611
2020's18 (9.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.52 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index101.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (4.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other179 (95.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]